Reducing Vertical Transmission of Hepatitis B in Africa

Status Recruiting

Clinical Trial Summary

Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the risk of hepatitis B transmission. The study will measure efficacy, safety, tolerability and adherence to medication.

Clinical Trial Description

The REVERT-B trial is a multi-center, phase III, randomized 2x2 factorial study designed to test the efficacy of early maternal TDF vs standard duration and neonatal 3TC prophylaxis compared to matching placebo in preventing HBV MTCT. Eligible pregnant women with HBV in prenatal care (n=450) will be randomized 1:1:1:1 to one of four maternal and neonatal prophylaxis combinations (shown as A-D in the figure below). Women will initiate daily oral TDF early (2nd trimester) or at the standard time per WHO guidelines (3rd trimester) and will continue TDF until delivery. The current WHO standard of care in pregnant women with HBV (EAg+) in Cameroon is TDF prophylaxis from 28 weeks until delivery. Newborns will receive liquid 3TC or matching placebo for the first six months of life to provide coverage until the vaccine series is complete. All infants in the study will be offered the 4-dose HBV vaccine series starting at birth. The 2x2 factorial design allows for two simultaneous studies where we first assess efficacy of early maternal prophylaxis (Aim 1) and secondarily assess efficacy of neonatal prophylaxis (Aim 2). The study endpoint for both aims is the MTCT rate (proportion of infants HBsAg+) at 6-9 months of age. Women and infants will be followed until 6-9 months after delivery and subaims will assess safety and adherence to maternal TDF and neonatal 3TC. Plasma testing will be used to measure medication adherence. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04704024
Study type	Interventional
Source	University of Alabama at Birmingham
Contact	Jodie Dionne, MD, MSPH
Phone	2059756530
Email	jdionne@uabmc.edu
Status	Recruiting
Phase	Phase 3
Start date	September 3, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02143401` - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Phase 1
Completed	`NCT00371150` - Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection	Phase 4
Active, not recruiting	`NCT03519113` - HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102	Phase 2/Phase 3
Completed	`NCT01788371` - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus	Phase 4
Recruiting	`NCT06368479` - Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings	N/A
Completed	`NCT01488526` - Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus	Phase 4
Terminated	`NCT02826018` - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection	Phase 1
Completed	`NCT01970254` - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
Completed	`NCT00489099` - A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)	Phase 3
Recruiting	`NCT03476083` - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission	Phase 4
Recruiting	`NCT03865966` - Hepatitis B Virus Infection After Liver Transplantation in Children
Completed	`NCT03627507` - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.	Phase 2/Phase 3
Completed	`NCT02443233` - Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong	N/A
Completed	`NCT00841477` - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users	Phase 3
Terminated	`NCT03887702` - Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors	Phase 3
Completed	`NCT02304315` - A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients	Phase 2
Active, not recruiting	`NCT05117541` - Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
Not yet recruiting	`NCT06368466` - A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Reducing Vertical Transmission of Hepatitis B in Africa — REVERT-B

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms